We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

66 hedge funds and large institutions have $195M invested in Avalo Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 2

397% more capital invested

Capital invested by funds: $39.1M → $195M (+$156M)

110% more call options, than puts

Call options by funds: $1.39M | Put options by funds: $659K

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

83% more funds holding

Funds holding: 36 → 66 (+30)

44.03% more ownership

Funds ownership: 72.44% → 116.46% (+44%)

Holders
66
Holders Change
+30
Holders Change %
+83.33%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
15
Reduced
8
Closed
2
Calls
$1.39M
Puts
$659K
Net Calls
+$726K
Net Calls Change
+$707K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.06M
2
CP
Caligan Partners
New York
+$7.17M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$7.03M
4
SCM
Silverarc Capital Management
Massachusetts
+$6.2M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.52M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$3.63M
2
RCM
RA Capital Management
Massachusetts
-$2.32M
3
RWP
RWA Wealth Partners
Massachusetts
-$1.5M
4
ACM
ADAR1 Capital Management
Texas
-$622K
5
UBS Group
UBS Group
Switzerland
-$331K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$119K +$80.4K +9,346 New
BC
52
BIT Capital
Germany
$24.5K +$16.6K +1,929 New
JP Morgan Chase
53
JP Morgan Chase
New York
$20K +$12.9K +1,499 +2,026%
PP
54
PFS Partners
New Jersey
$12.7K +$8.6K +1,000 New
Simplex Trading
55
Simplex Trading
Illinois
$9K +$6.43K +748 New
Citigroup
56
Citigroup
New York
$5.08K +$3.44K +400 New
Group One Trading
57
Group One Trading
Illinois
$3.57K +$2.41K +280 +28,000%
TRCT
58
Tower Research Capital (TRC)
New York
$330 +$224 +26 New
SS
59
SBI Securities
Japan
$292 +$9 +1 +5%
Morgan Stanley
60
Morgan Stanley
New York
$127 – – –
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$64 – – –
Osaic Holdings
62
Osaic Holdings
Arizona
$18 – – –
AWM
63
Activest Wealth Management
Florida
$13 – – –
KFI
64
Key Financial Inc
Pennsylvania
$13 – – –
PA
65
Parallel Advisors
California
$13 – – –
AI
66
Allostery Investments
Connecticut
– -$44.9K -9,000 Closed
Raymond James Financial
67
Raymond James Financial
Florida
– -$5 -1 Closed
1 2
3

AVTX Hedge Fund Activity: Q3 2025 in Review

66 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2025, worth a combined $195M — up 397% from $39.1M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new AVTX positions and 2 closed out — a net gain of 30 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $9.06M. The largest seller was Deep Track Capital, cutting an estimated $3.63M.

  • 66 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2025, up from 36 in Q2 2025.
  • Funds reported $195M of Avalo Therapeutics stock for Q3 2025, up 397% quarter-over-quarter.
  • 32 funds opened new Avalo Therapeutics positions in Q3 2025 and 2 closed out, a net change of +30 holders.
  • The largest Avalo Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $9.06M added.
  • The largest Avalo Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $3.63M sold.

Based on aggregated 13F filings for Q3 2025.